

TAXIME

Antibiotics

Recommended treatment of:

Elective and specific use in serious bacterial infections of ascertained or presumed origin, due to Gram-negative "difficile" organisms or mixed flora with presence of Gram-negative organisms resistant to the most common antibiotics.

In such infections, the product is indicated, in particular, in defeated and/or immunosuppressed patients. It is also indicated in the prophylaxis of surgical infections.

Route of administration:

TAXIME 500 mg/2ml, powder and solvent (WFI) for i.m. and i.v. injection

TAXIME 1 g/4ml, powder and solvent (WFI) for i.m. and i.v. injection

TAXIME 1 g /4ml, powder and solvent (Lidocaine HCl 1%) for i.m. injection

TAXIME 2 g/10ml, powder and solvent (WFI) for i.v. injection

Active principle:

Cefotaxime Sodium

Dosage & pack size:

500 mg/2ml – box of 1 vial with 500 mg of powder + 1 ampoule of 2 ml of WFI

1 g/4ml – box of 1 vial with 1 g of powder + 1 ampoule of 4 ml of WFI

1 g /4ml – box of 1 vial with 1 g of powder + 1 ampoule of 4ml of lidocaine hydrochloride at 1%

2 g/10ml – box of 1 vial with 2 g of powder + 1 ampoule of 10 ml of WFI

Registered for use in:

Italy

